share_log

Q1 2023 Earnings Estimate for Bluebird Bio, Inc. Issued By SVB Leerink (NASDAQ:BLUE)

Q1 2023 Earnings Estimate for Bluebird Bio, Inc. Issued By SVB Leerink (NASDAQ:BLUE)

SVB Leerink(纳斯达克股票代码:BLUE)发布的蓝鸟生物公司2023年第一季度收益预期
Defense World ·  2023/01/25 15:51

bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) – Equities researchers at SVB Leerink issued their Q1 2023 earnings per share estimates for shares of bluebird bio in a research report issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar anticipates that the biotechnology company will post earnings per share of ($0.64) for the quarter. SVB Leerink currently has a "Market Perform" rating and a $8.00 price objective on the stock. The consensus estimate for bluebird bio's current full-year earnings is ($4.36) per share. SVB Leerink also issued estimates for bluebird bio's Q2 2023 earnings at ($0.62) EPS and Q3 2023 earnings at ($0.58) EPS.

蓝鸟生物公司(纳斯达克:Blue-Get Rating)-SVB Leerink的股票研究人员在1月23日(星期一)发布的一份研究报告中发布了他们对蓝鸟生物股票2023年第一季度每股收益的预期。SVB Leerink分析师M.Foroohar预计,这家生物技术公司将公布本季度每股收益为0.64美元。SVB Leerink目前对该股的评级为“市场表现”,目标价为8美元。对蓝鸟生物目前全年收益的普遍预期是每股4.36美元。SVB Leerink还发布了蓝鸟生物2023年第二季度每股收益(0.62美元)和第三季度每股收益(0.58美元)的预期。

Get
到达
bluebird bio
蓝鸟传记
alerts:
警报:

BLUE has been the subject of several other research reports. Morgan Stanley raised their target price on bluebird bio from $3.00 to $4.00 and gave the stock an "underweight" rating in a research report on Tuesday. Royal Bank of Canada cut their target price on bluebird bio to $8.00 and set a "sector perform" rating for the company in a research report on Tuesday, November 8th. Finally, StockNews.com initiated coverage on bluebird bio in a research report on Wednesday, October 12th. They set a "sell" rating for the company. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $6.75.

蓝色一直是其他几份研究报告的主题。摩根士丹利在周二的一份研究报告中将蓝鸟生物的目标价从3.00美元上调至4.00美元,并给予该股“减持”评级。11月8日,加拿大皇家银行在一份周二的研究报告中将蓝鸟生物的目标价下调至8.00美元,并为该公司设定了“行业表现”评级。最后,StockNews.com在10月12日星期三的一份研究报告中开始了对蓝鸟生物的报道。他们为该公司设定了“卖出”评级。三位投资分析师对该股的评级为卖出,六位分析师给出了持有评级,一位分析师给出了买入评级。根据MarketBeat,该公司目前的平均评级为持有,平均目标价为6.75美元。

bluebird bio Trading Up 5.5 %

蓝鸟生物交易上涨5.5%

Shares of BLUE stock opened at $6.53 on Tuesday. The stock has a 50 day moving average of $7.40 and a two-hundred day moving average of $6.52. bluebird bio has a 12 month low of $2.87 and a 12 month high of $8.58. The company has a market capitalization of $541.49 million, a P/E ratio of -1.07 and a beta of 0.99.
周二,蓝色股票的开盘价为6.53美元。该股的50日移动均线切入位为7.40美元,200日移动均线切入位为6.52美元。蓝鸟生物的12个月低点为2.87美元,12个月高位为8.58美元。该公司市值为5.4149亿美元,市盈率为-1.07,贝塔系数为0.99。

bluebird bio (NASDAQ:BLUE – Get Rating) last announced its quarterly earnings data on Monday, November 7th. The biotechnology company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.28) by $0.36. bluebird bio had a negative return on equity of 173.58% and a negative net margin of 8,828.28%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $2.25 million.

青鸟生物(纳斯达克:Blue-Get Rating)上一次公布季度收益数据是在11月7日星期一。这家生物技术公司公布了该季度每股收益(0.92美元),比分析师普遍预期的(1.28美元)高出0.36美元。蓝鸟生物的净资产回报率为负173.58%,净利润率为负8,828.28%。该公司本季度营收为70万美元,而市场普遍预期为225万美元。

Insider Activity at bluebird bio

蓝鸟生物的内幕活动

In related news, Director Nick Leschly sold 4,290 shares of the firm's stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $7.80, for a total transaction of $33,462.00. Following the completion of the sale, the director now directly owns 280,149 shares of the company's stock, valued at approximately $2,185,162.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 9,506 shares of company stock valued at $72,088 in the last three months. Corporate insiders own 2.20% of the company's stock.

在相关新闻中,董事尼克·莱施利在1月11日星期三的一次交易中出售了4,290股该公司股票。该股以7.8美元的平均价格出售,总成交金额为33,462.00美元。出售完成后,董事现在直接拥有280,149股公司股票,价值约2,185,162.20美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在美国证券交易委员会网站。过去三个月,内部人士出售了9,506股公司股票,价值72,088美元。企业内部人士持有该公司2.20%的股份。

Institutional Investors Weigh In On bluebird bio

机构投资者参与蓝鸟生物

Hedge funds and other institutional investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY increased its stake in shares of bluebird bio by 142.4% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company's stock valued at $30,000 after buying an additional 2,744 shares during the period. US Bancorp DE increased its stake in shares of bluebird bio by 234.9% in the 3rd quarter. US Bancorp DE now owns 7,918 shares of the biotechnology company's stock valued at $50,000 after buying an additional 5,554 shares during the period. Amalgamated Bank bought a new position in shares of bluebird bio in the 1st quarter worth $39,000. PEAK6 Investments LLC bought a new position in shares of bluebird bio in the 2nd quarter worth $41,000. Finally, Laurion Capital Management LP bought a new position in shares of bluebird bio in the 2nd quarter worth $42,000. 79.01% of the stock is owned by institutional investors and hedge funds.

对冲基金和其他机构投资者最近对他们在该公司的头寸进行了调整。纽约大都会人寿保险公司在第三季度增持了蓝鸟生物的股份142.4%。纽约大都会人寿保险公司现在持有这家生物技术公司4671股股票,价值3万美元,在此期间又购买了2744股。美国Bancorp DE在第三季度增持了蓝鸟生物的股份234.9%。US Bancorp DE现在持有这家生物技术公司7918股股票,价值5万美元,在此期间又购买了5554股。合并银行在第一季度购买了蓝鸟生物的新头寸,价值3.9万美元。Peak6 Investments LLC在第二季度购买了蓝鸟生物的新头寸,价值41,000美元。最后,Laurion Capital Management LP在第二季度购买了蓝鸟生物的新头寸,价值42,000美元。79.01%的股票由机构投资者和对冲基金持有。

About bluebird bio

关于蓝鸟传记

(Get Rating)

(获取评级)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

蓝鸟生物公司是一家生物技术公司,研究、开发和商业化针对严重遗传病的变革性基因疗法。其用于治疗严重遗传性疾病的候选产品包括用于治疗输血依赖型β-地中海贫血的贝替贝吉基因Autotemcel;用于治疗镰状细胞病(SCD)的lovotieglogene autemcel;以及用于治疗大脑肾上腺脑白质营养不良的伊利伐多烯Autotemcel。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
  • High-Yield, Deep-Value Verizon Puts In A Bottom
  • Can Coty Stock Emerge in 2023 With Upside
  • Should You Bet Against The Nasdaq 100 With This Inverse ETF?
  • Insiders Buy Archer Aviation, Is This Stock About To Take Off?
  • Intuit Is About To Make a Move, But Which Way?
  • 免费获取StockNews.com关于蓝鸟生物的研究报告(蓝色)
  • 高收益、高价值的Verizon陷入谷底
  • 科蒂股票能否在2023年出现上行
  • 你应该用这只反向ETF做空纳斯达克100指数吗?
  • 业内人士买入阿彻航空,这只股票要起飞了吗?
  • Intuit即将采取行动,但走哪条路呢?

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

获得蓝鸟生物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对蓝鸟生物和相关公司的最新新闻和分析师评级的每日简明摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发